Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus

Overview

The purpose of this research study is to see the effect of taking Aged Garlic Extract (AGE) on the progression of coronary plaque, a condition called atherosclerosis, in people diagnosed with Diabetes.

Full Title of Study: “Effect of Aged Garlic Extract (AGE) on Progression of Coronary Atherosclerosis in Persons With Type 2 Diabetes Mellitus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 7, 2018

Detailed Description

This clinical trial is to determine on progression rates of low attenuation plaque under influence of Aged Garlic Extract as compared to placebo over the 1year period in individuals with Type 2 Diabetes Mellitus.The study also examines the effect of Aged Garlic Extract on endothelial function and arterial stiffness which was measured by cardio-ankle vascular index (CAVI) over the 3months period.

Interventions

  • Dietary Supplement: Aged Garlic Extract (AGE)
    • 2400mg of Aged Garlic Extract (AGE)
  • Dietary Supplement: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Active Comparator: Aged Garlic Extract (AGE)
    • 2400mg of Aged Garlic Extract (AGE)
  • Placebo Comparator: Placebo
    • The Placebo does not contain any Aged Garlic Extract (AGE)

Clinical Trial Outcome Measures

Primary Measures

  • Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.
    • Time Frame: 12 months
    • Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.

Secondary Measures

  • Rate of change in inflammatory biomarkers (CRP,IL-6)
    • Time Frame: 12 months
    • Rate of change in inflammatory biomarkers
  • Rate of change in endothelial function
    • Time Frame: 3 months and 12 months
    • Endothelial Function and arterial stiffness measured by cardio-ankle vascular index (CAVI)

Participating in This Clinical Trial

Inclusion Criteria

  • Age 30-75 years
  • Known Diabetes Mellitus (HgA1c >6.5%, fasting blood sugar >125 mg/dl, taking anti diabetes medications)
  • Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
  • Calcium Score >20 at baseline

Exclusion Criteria

  • A contraindication to AGE including: known hypersensitivity to drug.
  • Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
  • Weight in excess of 350 pounds
  • Bleeding disorder
  • History of known coronary artery disease, myocardial infarction, stroke or life threatening arrhythmia within the prior six months
  • NYHA Class II- IV heart failure
  • History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
  • Serum creatinine > 1.4 mg/dl
  • Triglycerides > 400 at visit 1
  • Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
  • Concurrent enrollment in another placebo-controlled trial
  • Partial ileal bypass or known gastrointestinal disease limiting drug absorption
  • Current tobacco use
  • Current use of anticoagulants (except for anti-platelet agents)
  • Renal failure
  • History of hypertensive encephalopathy or cerebrovascular accident
  • Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI
  • Pregnancy

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Matthew J. Budoff, Principal Investigator – Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.